MorphoSys AG Logo

MorphoSys AG

ISIN

DE0006632003

Ticker

MOR

Sector

Health Care

Sub-Industry

Pharmaceuticals

Country

Germany

Year Founded

1992

About MorphoSys AG

Company Description

MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines.

Our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical company, we are driven by the urgency to deliver groundbreaking medicines, aspiring to give more life for people with cancer.

Headcount

732

Served Area

Worldwide

Headquarters

Semmelweisstr. 7
82152, Planegg
Germany

Filings & Publications

  • Consolidated Report 2021 - Q1 English 🇬🇧
  • Consolidated Report 2021 - Q1 German 🇩🇪
  • Consolidated Report 2021 - Q2 German 🇩🇪
  • Consolidated Report 2021 - Q2 English 🇬🇧
  • Consolidated Report 2021 - Q3 German 🇩🇪
  • Consolidated Report 2021 - Q3 English 🇬🇧
  • Consolidated Report 2021 - Q4 English 🇬🇧
  • Consolidated Report 2020 - Q1 German 🇩🇪
  • Consolidated Report 2020 - Q1 English 🇬🇧
  • Consolidated Report 2020 - Q2 German 🇩🇪
  • Consolidated Report 2020 - Q2 English 🇬🇧
  • Consolidated Report 2020 - Q3 German 🇩🇪
  • Consolidated Report 2020 - Q3 English 🇬🇧
  • Consolidated Report 2020 - Q4 English 🇬🇧
  • Consolidated Report 2019 - Q1 German 🇩🇪
  • Consolidated Report 2019 - Q1 English 🇬🇧
  • Consolidated Report 2019 - Q2 German 🇩🇪
  • Consolidated Report 2019 - Q2 English 🇬🇧
  • Consolidated Report 2019 - Q3 English 🇬🇧
  • Consolidated Report 2019 - Q3 German 🇩🇪
  • Consolidated Report 2019 - Q4 German 🇩🇪
  • Consolidated Report 2019 - Q4 English 🇬🇧
  • Consolidated Report 2018 - Q3 German 🇩🇪
  • Consolidated Report 2018 - Q3 English 🇬🇧
  • Consolidated Report 2018 - Q4 German 🇩🇪
  • Consolidated Report 2018 - Q4 English 🇬🇧
  • Consolidated Report 2022 - Q1 German 🇩🇪
  • Consolidated Report 2022 - Q1 English 🇬🇧
  • Consolidated Report 2022 - Q2 English 🇬🇧
  • Consolidated Report 2022 - Q3 English 🇬🇧

Insider Trades

Date Trading entity / Person Association Trade type Volume
20.09.2023 Cluzel, Dr. Marc Supervisory board Buy EUR 775.25
07.06.2023 Cluzel, Dr. Marc Supervisory board Buy EUR 52,800.00
06.06.2023 Cluzel, Dr. Marc Supervisory board Buy EUR 24,280.00
30.11.2022 Reissner, Thomas Supervisory board Buy EUR 13,800.00
30.11.2022 Reissner, Thomas Supervisory board Buy EUR 7,479.00
30.11.2022 Reissner, Thomas Supervisory board Buy EUR 4,186.00
30.11.2022 Reissner, Thomas Supervisory board Buy EUR 2,698.00
29.11.2022 Reissner, Thomas Supervisory board Buy EUR 8,100.00
29.11.2022 Reissner, Thomas Supervisory board Buy EUR 5,000.00
28.11.2022 Vermeylen, Krisja Supervisory board Buy EUR 14,860.00

Capital Markets Information

ISIN

DE0006632003

LEI

529900493806K77LRE72

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Frankfurt Stock Exchange

Stock Index

SDAX

TecDAX

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.